Ciprofloxacin

Restricted
C. diff Risk

High

Oral Bioavailability

Excellent

Spectrum Of Activity

Dosing

Fluoroquinolones should be avoided in pediatric patients whenever possible

Mild to moderate infections
10 mg/kg/dose PO every 12 hr (500 mg/dose max)

Severe infections
15-20 mg/kg/dose PO every 12 hr (750 mg/dose max)

10 mg/kg/dose IV every 8-12 hr (400 mg/dose max)

Reserved for Pediatrics

General Information

  • QTc prolongation

  • Dysglycemia

  • Tendinopathy and rupture

  • GI upset

  • Rash

  • Retinal detachment

  • CNS toxicity including confusion, psychosis

  • Weakness exacerbation in myasthenia gravis

Pseudomonal and other gram negative infections of urinary tract, bone/joint, abdomen and other sites

Clinical

  • Monitor QTc in patients with increased risk

  • Increased INR (warfarin)

  • Hypersensitivity

  • GI effects

  • tendonitis

CYP1A2 inhibitor - Multiple interactions possible.

QTc prolongation - Increased risk with other agents that prolong QTc.

Divalent & trivalent cations including Al, Ca, Fe, Mg (antacids, dairy products, iron supplements, some enteral feeds) - Decreased absorption

Cyclosporine - Increased levels of cyclosporine

Warfarin - Increased INR

Methadone - Lowered seizure threshold

Antimicrobial class: Fluoroquinolone

Pregnancy category: C

Average serum half life: 4 hours

Biliary penetration: Therapeutic

CSF penetration: Moderate

Lung penetration: Therapeutic

Urine penetration: Therapeutic